ProCertus BioPharm procertus.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

ProCertus BioPharm develops and commercializes pharmaceutical products that prevent the common side effects of cancer therapy.

ProCertus BioPharm develops and commercializes pharmaceutical products that prevent the common side effects of cancer therapy.

Company (Alive / Active)

Phone: 608-441-2880

Fax:

505 South Rosa Road
Suite 175 B
Madison, 53719
Wisconsin, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
ProCertus BioPharm $6.1M Apr 5, 2011
See all 13 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related ProCertus BioPharm Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 4 investors

Competitors

Company Status Description Investors

Pharmasset

Princeton, New Jersey, United States
AcquiredPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Pharmasset's research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. In January 2012, Pharm...Show allLogin to see details

Agensys

Santa Monica, California, United States
AcquiredAgensys, Inc. is developing a pipeline of therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumor cancers based on its own proprietary targets. The Company has discovered and validated a rich portfolio of novel, clinically relevant cancer targets to 14 different cancer types that have been carefully selected to enable development of new effective therapeutics with fewer and less severe side effects. All of Agensys' cancer targets must meet the following criteria: (1) a novel mo...Show allLogin to see details
See all 13 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Formulation of small adrenergic agonist salt forms in organic solvents Mar 09, 2012 Application